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IMPORTANCE Coronavirus disease 2019 (COVID-19) affects the nervous system in adult
patients. The spectrum of neurologic involvement in children and adolescents is unclear.
OBJECTIVE To understand the range and severity of neurologic involvement among children
and adolescents associated with COVID-19.
SETTING, DESIGN, AND PARTICIPANTS Case series of patients (age <21 years) hospitalized
between March 15, 2020, and December 15, 2020, with positive severe acute respiratory
syndrome coronavirus 2 test result (reverse transcriptase-polymerase chain reaction and/or
antibody) at 61 US hospitals in the Overcoming COVID-19 public health registry, including
616 (36%) meeting criteria for multisystem inflammatory syndrome in children. Patients with
neurologic involvement had acute neurologic signs, symptoms, or diseases on presentation
or during hospitalization. Life-threatening involvement was adjudicated by experts based on
clinical and/or neuroradiologic features.
EXPOSURES Severe acute respiratory syndrome coronavirus 2.
MAIN OUTCOMES AND MEASURES Type and severity of neurologic involvement, laboratory
and imaging data, and outcomes (death or survival with new neurologic deficits) at hospital
discharge.
RESULTS Of 1695 patients (909 [54%] male; median [interquartile range] age, 9.1 [2.4-15.3]
years), 365 (22%) from 52 sites had documented neurologic involvement. Patients with
neurologic involvement were more likely to have underlying neurologic disorders (81 of
365 [22%]) compared with those without (113 of 1330 [8%]), but a similar number were
previously healthy (195 [53%] vs 723 [54%]) and met criteria for multisystem inflammatory
syndrome in children (126 [35%] vs 490 [37%]). Among those with neurologic involvement,
322 (88%) had transient symptoms and survived, and 43 (12%) developed life-threatening
conditions clinically adjudicated to be associated with COVID-19, including severe
encephalopathy (n = 15; 5 with splenial lesions), stroke (n = 12), central nervous system
infection/demyelination (n = 8), Guillain-Barré syndrome/variants (n = 4), and acute
fulminant cerebral edema (n = 4). Compared with those without life-threatening conditions
(n = 322), those with life-threatening neurologic conditions had higher neutrophil-to-
lymphocyte ratios (median, 12.2 vs 4.4) and higher reported frequency of D-dimer greater
than 3 μg/mL fibrinogen equivalent units (21 [49%] vs 72 [22%]). Of 43 patients who
developed COVID-19–related life-threatening neurologic involvement, 17 survivors (40%)
had new neurologic deficits at hospital discharge, and 11 patients (26%) died.
CONCLUSIONS AND RELEVANCE In this study, many children and adolescents hospitalized for
COVID-19 or multisystem inflammatory syndrome in children had neurologic involvement,
mostly transient symptoms. A range of life-threatening and fatal neurologic conditions
associated with COVID-19 infrequently occurred. Effects on long-term neurodevelopmental
outcomes are unknown.
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-19 as a global pandem
ic.
C oronaviruses primarily cause respiratory disease; how-ever, severe acute respiratory syndrome coronavirus(SARS-CoV), Middle East respiratory syndrome coro-
navirus, and newly identified SARS-CoV-2 have been associ-
ated with a range of disorders of the peripheral and central
nervous system (CNS).1-9 Early reports from Wuhan, China,
described a spectrum of neurologic conditions associated
with SARS-CoV-2 infection in 36% of 214 adults hospitalized
with coronavirus disease 2019 (COVID-19).10 Reported neuro-
logic and psychiatric symptoms in adult patients with COVID-19
include anosmia/ageusia,11,12 headaches,13 dizziness/ataxia,10
psychosis, dementia, depression, anxiety, and mania.14 Re-
ported severe neurologic involvement in adult patients with
COVID-19 includes acute encephalopathy or encephalitis,15-18
acute necrotizing encephalopathy,19,20 epilepsy/seizures,21,22
acute transverse myelitis,23-25 Guillain-Barré syndrome
(GBS),26,27 posterior reversible encephalopathy syndrome,28
and acute ischemic or hemorrhagic stroke.14,29-34
Although most children and adolescents are spared from
severe COVID-19, there have been reports of life-threatening
neurologic involvement in patients developing multisystem
inflammatory syndrome in children (MIS-C), a relatively rare,
hyperinflammatory, severe illness temporally associated with
SARS-CoV-2 infection, presumably postinfectious.35,36 Across
case series published between March and August 14, 2020, be-
tween 6% and 58% of children and adolescents hospitalized
with MIS-C developed central and/or peripheral nervous sys-
tem involvement.36-40 The frequency of neurologic involve-
ment in children hospitalized with acute COVID-19 is unclear
with 150 of 4190 patients reported across 9 international case
series.41-46 Using the Overcoming COVID-19 US public health
surveillance registry of children and adolescents hospital-
ized with COVID-19–related complications,36 we aimed to de-
scribe the type and severity of neurologic involvement and
documented hospital outcomes.
Methods
Study Design and Participants
Active surveillance was performed at 61 hospitals in 31 states
in the Overcoming COVID-19 network to identify children
and adolescents (age <21 years) with SARS-CoV-2–related
illness hospitalized from March 15, 2020, to December 15,
2020. The study was approved by the central institutional
review board at Boston Children’s Hospital and determined
to meet the requirement of public health surveillance as
defined in 45 CFR 46.102(I)(2) at Boston Children’s Hospital
and the US Centers for Disease Control and Prevention under
a waiver of consent.
Patients were included if they were hospitalized for acute
illness at a participating site, were younger than 21 years, had
a positive SARS-CoV-2 test result (reverse transcriptase–
polymerase chain reaction and/or antibody) and symptoms
associated with acute COVID-19, or met US Centers for Dis-
ease Control and Prevention criteria for MIS-C (eTable 1 in
Supplement 1).47 Patients were excluded if they had asymp-
tomatic SARS-CoV-2 infection or a non–COVID-19–related cause
for hospitalization or death. Race and ethnicity were ex-
tracted from the patient’s medical record and included to evalu-
ate risk of neurologic involvement.
Classification of Neurologic Involvement
Patients were stratified by the presence of neurologic
involvement, defined as (1) suspected acute neurologic dis-
ease (eg, CNS infection/demyelination or stroke) on presen-
tation or that developed during hospitalization (eMethods in
Supplement 1) or (2) acute neurologic signs or symptoms on
presentation.
Severity of neurologic involvement was adjudicated by
neurology and critical care experts on the central study team
(K.L.L., B.J.R., T.Y.P., and A.G.R.; eMethods in Supplement 1).
Cases were classified as life-threatening based on clinical and/or
neuroradiologic features associated with more severe out-
comes and included the following diagnoses: acute CNS in-
fection (aseptic meningitis, encephalitis by International
Encephalitis Consortium definition,48 and Brighton criteria49),
central demyelinating disorder (acute disseminated encepha-
lomyelitis [ADEM]), acute ischemic or hemorrhagic stroke, GBS
and variants, or severe encephalopathy with or without COVID-
19–related neuroimaging abnormalities (eg, virus-associated
necrotizing disseminated acute leukoencephalopathy50 and/or
cytotoxic splenial lesions44,51,52). Cases with neurologic
involvement that did not meet any of these criteria and
had cerebrospinal fluid and/or neuroimaging results that
were normal or not performed were categorized as non–life-
threatening neurologic involvement.
Neurologic Outcome Classification
Neurology and critical care experts (K.L.L., B.J.R., and A.G.R.)
determined through case review and consensus whether life-
threatening neurologic conditions were directly associated with
COVID-19 or secondary to exacerbation of primary neuro-
logic disease or complication of critical illness associated with
COVID-19. Sites with abnormal neuroimaging studies sent dei-
dentified brain magnetic resonance imaging (MRI) and com-
puted tomography studies for central review. Images were re-
viewed by a pediatric neuroradiologist (T.Y.P.) and discussed
with a pediatric neurologist (K.L.L.) reaching consensus opin-
ion about whether the clinicoradiologic link was directly as-
sociated with COVID-19 or secondary to an alternate etiology
Key Points
Question What is the extent of neurologic involvement in
US hospitalized children and adolescents with coronavirus
disease 2019 (COVID-19)?
Findings In this study of 1695 patients 21 years or younger
hospitalized for acute COVID-19 or multisystem inflammatory
syndrome, 365 (22%) had neurologic involvement. Forty-three
patients (12%) developed COVID-19–related life-threatening
neurologic disorders, 11 (26%) died, and 17 (40%) survived with
new neurologic sequelae.
Meaning In this study, COVID-19–related neurologic involvement
was common in hospitalized children and adolescents and mostly
transient.
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(eg, extracorporeal membrane oxygenation [ECMO] or preex-
isting neurologic condition).
Outcomes were determined at hospital discharge. Neuro-
logic deficits were defined as gross impairment in motor,
cognitive, or speech and language functions. Psychiatric se-
quelae (eg, anxiety, depression, and/or suicidal ideation) were
not included. New neurologic deficits were determined by
medical record review at each site and adjudicated by the
experts for all patients with and without neurologic involve-
ment (eMethods in Supplement 1).
Statistical Analyses
We report the frequency of clinical characteristics, underly-
ing conditions, type of neurologic involvement on admission
or during hospitalization, and hospital outcomes. Continu-
ous variables were expressed as medians and interquartile
range. Categorical variables were expressed as counts and per-
centages. Between-group differences were analyzed using a
χ2 test, Fisher exact test, or Kruskal-Wallis test where appro-
priate. Two-sided P values less than .05 were considered
statistically significant. We did not impute missing data. We
analyzed all data using R software, version 3.6.1 (R Project for
Statistical Computing).
Results
Demographics and Clinical Characteristics
Among All Patients
From March 15, 2020, to December 15, 2020, a total of 1784
hospitalized children and adolescents with COVID-19–
related illness were reported to the registry. Of these, 89 pa-
tients were excluded on the basis of being 21 years or older
(n = 27), epidemiologic link to SARS-CoV-2 without a positive
test result (n = 54), and non–COVID-19–related cause for hos-
pitalization or death (n = 8) (eFigure in Supplement 1). We de-
scribe 1695 patients (909 male [54%]; median [interquartile
range] age, 9.1 [2.4-15.3] years) from 61 sites in 31 states (Table 1).
Most patients were either Hispanic or Latino (638 of 1695 [38%])
or non-Hispanic Black (442 of 1695 [26%]).
Neurologic vs Nonneurologic Involvement
There were 365 patients (22%) with neurologic involvement
reported from 52 sites in 29 states. The characteristics of the
patients with and without neurologic involvement are shown
in Table 1. The frequencies of previously healthy patients
(195 [53%] vs 723 [54%]) and patients meeting MIS-C criteria
(126 [35%] vs 490 [37%]) were similar. Patients with neuro-
logic involvement were more likely to have underlying neu-
rologic disorders (81 [22%]) compared with those without
(113 [8%]), including seizure disorders, neuromuscular disor-
ders, and autism or developmental delay. Presenting neuro-
logic signs and symptoms differed by age with seizures or sta-
tus epilepticus most common in children younger than 5 years
and anosmia and/or ageusia most common in patients be-
tween ages 13 and 20 years (Figure 1A).
Most patients with and without neurologic involvement
were discharged alive (351 [96%] and 1322 [99%], respec-
tively). Children with neurologic involvement had a higher rate
of survival with new neurologic deficits (20 of 365 [5%]) com-
pared with those without COVID-19–associated neurologic
involvement (2 of 1330 [0.2%]) (Table 1). Neurologic deficits
in those without neurologic involvement included cognitive
and motor impairments as a result of sequelae of critical ill-
ness and intensive care therapies.
Life-threatening Neurologic Involvement
Among 365 patients with neurologic involvement, 43 (12%)
had life-threatening neurologic involvement associated with
COVID-19 (Table 2). Among these, 34 of 43 (79%) had no ma-
jor underlying conditions, 20 (47%) met criteria for MIS-C,
and 3 (7%) had a preexisting neurologic disorder. Life-
threatening neurologic conditions included severe encepha-
lopathy (n = 15; 5 with white-matter hyperintensities and sple-
nial lesions), acute ischemic or hemorrhagic stroke (n = 12),
acute CNS infection/ADEM (n = 8), acute fulminant cerebral
edema (n = 4), and GBS (n = 4) (Table 2; eTable 2 in Supple-
ment 1). Eight patients with stroke had underlying risk fac-
tors (5 experienced stroke during ECMO [eTable 3 in Supple-
ment 1]; 2 were attributed to possible COVID-19–related
exacerbation of an underlying primary neurologic disorder
[eg, arteriovenous malformation rupture and ischemic stroke
in a patient with history of moyamoya syndrome]; and a pre-
viously healthy patient presented with a new diagnosis of acute
myelogenous leukemia). Four patients were previously healthy
and did not have stroke risk factors (eTable 4 in Supple-
ment 1). Five children with severe encephalopathy had brain
MRI findings of diffuse white-matter hyperintensities on
T2-weighted images and restricted diffusion in the periven-
tricular white matter, deep white matter, and/or corpus callo-
sum (60% with MIS-C; 3 of 5 with unfavorable neurologic
outcomes). Representative CNS images from patients with life-
threatening neurologic involvement associated with COVID-19
are shown in Figure 2 and Figure 3.
Compared with those with non–life-threatening neuro-
logic involvement, children with life-threatening neurologic
disease were more likely to undergo lumbar puncture (20 of
43 [47%] vs 72 of 322 [22%]), head computed tomography
(23 of 43 [53%] vs 40 of 322 [12%]) or brain MRI (26 of 43
[60%] vs 28 of 322 [9%]). The cerebrospinal fluid results
showed unremarkable findings in both groups (eTable 5 in
Supplement 1). As shown in Figure 1B, patients with life-
threatening neurologic conditions were more inflamed and
coagulopathic than those with no or non–life-threatening
neurologic involvement. Patients with life-threatening vs
non–life-threatening neurologic involvement had higher
neutrophil-to-lymphocyte ratios (median, 12.2 vs 4.4), and
higher reported frequency of D-dimer >3 μg/mL fibrinogen
equivalent units (21 [49%] vs 72 [22%]; to convert D-dimer to
nanomoles per liter, multiply by 5.476; Figure 1; eTable 6 in
Supplement 1).
In patients who developed life-threatening neurologic in-
volvement, 11 (26%) died and 17 (40%) were discharged from
hospital with new neurologic deficits (Table 2). Of survivors
with new deficits, 16 (94%) were previously healthy, none had
prior neurologic disorders, 7 (41%) met MIS-C criteria, and
Neurologic Involvement in Children and Adolescents With COVID-19 or Multisystem Inflammatory Syndrome Original Investigation Research
jamaneurology.com (Reprinted) JAMA Neurology Published online March 5, 2021 E3
© 2021 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ on 03/15/2021
Table 1. Characteristics and Outcomes of 1695 Patients (Age <21 Years) Hospitalized for COVID-19–Related Illness











Male 909 (54) 204 (56) 705 (53)
.36
Female 786 (46) 161 (44) 625 (47)
Age, median (IQR), y 9.1 (2.4-15.3) 9.2 (2.5-15.6) 9.0 (2.4-15.1) .94
Race/ethnicitya
Non-Hispanic
White 311 (18) 83 (23) 228 (17)
.004
Black 442 (26) 108 (30) 334 (25)
Hispanic or Latino 638 (38) 125 (34) 513 (39)
Other race, non-Hispanic 111 (7) 21 (6) 90 (7)
Unknown 216 (13) 31 (8) 185 (14)
SARS-CoV-2 testing
RT-PCR performed 1589 (94) 359 (98) 1230 (92) <.001
Positive RT-PCR result 1248 (74) 298 (82) 950 (71) <.001
Antibody test performed 672 (40) 140 (38) 532 (40) .61
Positive antibody test result 589 (35) 121 (33) 468 (35) .51
Underlying conditionb
Previously healthyc 918 (54) 195 (53) 723 (54) .80
≥1 Comorbidity, excluding
obesity
714 (42) 156 (43) 558 (42) .83
Neurological, any condition 194 (11) 81 (22) 113 (8) <.001
Seizure disorder 100 (6) 57 (16) 43 (3) <.001
Neuromuscular disordersd 59 (3) 25 (7) 34 (3) <.001
Autism or developmental delay 42 (2) 18 (5) 24 (2) .001
Static encephalopathy 40 (2) 18 (5) 22 (2) <.001
Congenital neurologic disorderse 35 (2) 16 (4) 19 (1) <.001
Prior stroke/HIE 15 (1) 6 (2) 9 (1) .11
Respiratory 321 (19) 75 (21) 246 (18) .42
Cardiac 110 (6) 25 (7) 85 (6) .85
Gastrointestinal 173 (10) 44 (12) 129 (10) .22
Oncologic or immune
compromised
122 (7) 17 (5) 105 (8) .04
Hematological 88 (5) 17 (5) 71 (5) .70
Kidney 72 (4) 13 (4) 59 (4) .56
Endocrine 129 (8) 25 (7) 104 (8) .61
Genetic or metabolic
(not obesity)
69 (4) 23 (6) 46 (3) .02
Clinically diagnosed obesityf 184 (11) 39 (14) 145 (14) >.99
Non-CNS organ system involvement
Met MIS-C criteria 616 (36) 126 (35) 490 (37) .45
Other organ systems involved
None 182 (11) 36 (10) 146 (11) .61
1 341 (20) 74 (20) 267 (20) .99
2 319 (19) 64 (18) 255 (19) .53
3 286 (17) 56 (15) 230 (17) .42
4 567 (34) 135 (37) 432 (33) .12
(continued)
Research Original Investigation Neurologic Involvement in Children and Adolescents With COVID-19 or Multisystem Inflammatory Syndrome
E4 JAMA Neurology Published online March 5, 2021 (Reprinted) jamaneurology.com
© 2021 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ on 03/15/2021
14 (82%) required rehabilitative services on discharge (eTable 2
in Supplement 1).
Association of COVID-19 Neurologic Involvement
With Fatality
Fourteen patients with COVID-19 neurologic involvement died
in the hospital. Three deaths were associated with acute
COVID-19 cardiorespiratory disease. Two patients with asthma
had cardiac arrest on hospital presentation, and 1 previously
healthy teenager with anosmia/ageusia died of multiorgan fail-
ure. These patients were excluded from further evaluation. The
other 11 deaths were classified by expert consensus as either
directly associated with COVID-19 neurologic involvement or
with catastrophic neurologic events secondary to COVID-19–
related critical illness (Table 2). These cases are briefly sum-
marized below (eTable 2 in Supplement 1).
Three previously healthy children with acute fulminant ce-
rebral edema died within 48 hours of hospital admission
(eTable 7 in Supplement 1). One male infant with COVID-19 pre-
sented with fever, seizures, and gastrointestinal symptoms and
within 24 hours of hospitalization developed status epilepti-
cus and had a cardiac arrest, with subsequent imaging show-
ing global cerebral edema. One elementary school–aged girl
presented with fever and sore throat, then developed status
epilepticus with subsequent imaging revealing cerebral edema
with tonsillar herniation. One elementary school–aged boy met
criteria for MIS-C 1 month after a positive SARS-CoV-2 respi-
ratory test result. He developed status epilepticus shortly af-
ter hospital admission and imaging showed global cerebral
edema and uncal herniation.
Four patients with stroke died. Three of these patients had
strokes with malignant edema and examinations consistent
with brain death on ECMO. The fourth died of multiple ische-
mic strokes owing to rapidly progressive large-vessel CNS vas-
culitis despite intensive immunotherapies.
Four patients who developed severe encephalopathy died.
One immunocompromised adolescent with leukemia and acute
COVID-19 pneumonia had diffuse T2 prolongation and re-
duced diffusivity in the bilateral periventricular white mat-
ter, with involvement of the splenium and genu of the corpus
callosum, who also developed acute motor-sensory axonal
neuropathy confirmed by electromyography/nerve conduc-
tion study. Two other patients who died required intubation
for severe encephalopathy, complicated by cardiovascular col-
lapse with cannulation for venoarterial ECMO and progres-
sion to brain death. One teenager with obesity who died had
preexisting hypertension and diabetes and received venoar-
terial ECMO for cardiorespiratory failure. A brain MRI on de-
cannulation obtained for prolonged encephalopathy showed
multifocal areas of restricted diffusion and hemorrhage
throughout the posterior white matter and brainstem.
Discussion
In a large, multicenter case series of US children and adoles-
cents hospitalized with acute COVID-19 or MIS-C, 22% of re-
ported patients had neurologic involvement. Approximately
half of patients with and without neurologic involvement were
previously healthy, a similar percentage had MIS-C, but more
Table 1. Characteristics and Outcomes of 1695 Patients (Age <21 Years) Hospitalized for COVID-19–Related Illness












ICU 836 (49) 227 (62) 609 (46) <.001
ECMO 32 (2) 16 (4) 18 (1) <.001
Mechanical ventilation 225 (13) 103 (28) 122 (9) <.001
Length of stay, median (IQR), d
ICU 4 (2-7) 4 (2-9) 4 (2-6) .02
Hospital 5 (2-9) 5 (2-11) 5 (2-8) .004
Died 22 (1) 14 (4) 8 (1) <.001
Survived, new neurological deficit 22 (1) 20 (5) 2 (0.2) .02
Discharged to rehabilitation 25 (1) 13 (4) 12 (1) <.001
Abbreviations: CNS, central nervous system; COVID-19, coronavirus disease
2019; ECMO, extracorporeal membrane oxygenation; HIE, hypoxic ischemic
encephalopathy; ICU, intensive care unit; IQR, interquartile range;
MIS-C, multisystem inflammatory syndrome in children; RT-PCR, reverse
transcriptase–polymerase chain reaction; SARS-CoV-2, severe acute respiratory
syndrome coronavirus 2.
a Race and ethnic group were reported by the patient or by the patient’s parent
or guardian. Race/ethnicity categories are not mutually exclusive.
b Patients may have more than 1 underlying condition.
c Previously healthy was defined as an absence of reported underlying
conditions and taking no prescription medications.
d Neuromuscular disorders include spastic quadriplegia, muscular dystrophy,
neuromuscular weakness, and neuromuscular scoliosis.
e Congenital neurologic disorders include hydrocephalus, neurogenetic, and
neurometabolic disorders.
f The determination of clinically diagnosed obesity was based on reporting by
clinicians among patients who were aged at least 2 years (n = 278 for patients
with neurological involvements and n = 1017 for patients without neurological
involvement).
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patients with neurologic involvement had underlying neuro-
logic disorders (22% vs 8%). Neurologic involvement in most
patients was transient and resolved by hospital discharge; how-
ever, 43 patients (12%) developed a range of life-threatening
neurologic conditions associated with COVID-19, and 66% of
these patients had unfavorable outcomes, including death or
new neurologic disability at hospital discharge.
The range of neurologic symptoms associated with
COVID-19 in children and adolescents was broad and varied
by age including seizures/status epilepticus in the younger
patients and reports of anosmia and/or ageusia, headache, and
fatigue/weakness in older patients. Approximately 1 in 4 pa-
tients with neurologic involvement across age groups pre-
sented with altered awareness or confusion. The range of
severe neurologic complications including peripheral nerve dis-
orders (GBS and variants), focal CNS disease (ischemic stroke
due to large vessel occlusion, cerebral venous sinus thrombo-
sis, and focal cerebral arteriopathy), and diffuse CNS involve-
ment (CNS infection, ADEM, severe encephalopathy with white
matter and corpus callosum lesions, and acute fulminant ce-
rebral edema) make it likely that multiple mechanisms under-
lie this wide spectrum of disease. These include putative
mechanisms such as neuroinvasive or neurotropic (direct
viral entry and/or neuronal infection via angiotensin-
converting enzyme 253,54 and/or olfactory tract55,56), neuro-
inflammatory (exaggerated cytokine/immune mediated re-
sponse leading to blood brain barrier breakdown57,58),
postinfectious immune dysregulation,59,60 and/or as second-
ary injury from complications of systemic inflammation or
other non-CNS organ failure.61
We observed 4 cases of GBS that presented with classic
neurologic signs, symptoms, and electrophysiologic features
within 1 month following SARS-CoV-2 exposure, similar to re-
ports in adults and children in association with COVID-19,26,27
and 1 case of acute motor-sensory axonal neuropathy. Ani-
mal models and clinicopathological evidence support an au-
toimmune mechanism and potential molecular mimicry be-
tween antibodies against myelin and gangliosides in the
nervous system and recent infectious agents, now including
COVID-19 infection,62,63 and suggests a potential role for an-
tiganglioside antibodies in immunomodulatory therapies.
We report 12 cases of acute ischemic or hemorrhagic stroke,
with 8 having underlying stroke risk factors. Five of these cases
occurred while receiving ECMO, but were included because
Figure 1. Presenting Neurologic Symptoms and Most Abnormal Laboratory Values in Patients (Age <21 Years) Hospitalized
for Coronavirus Disease 2019 (COVID-19)
Presenting symptoms by ageA
Difficulty walking or crawling
Seizures or status epilepticus
Loss of sense of taste
Loss of sense of smell
Headache
Alerted awareness or confusion
Fatigue/weakness
Patients, %
0 20 40 60 80




C-reactive protein >10 mg/dL
D-dimer >3 μg/mL FEU
















<5 y (n = 118)
5-12 y (n = 119)
13-20 y (n = 128)
A, Presenting neurologic symptoms by age in 365 patients (age <21 years) with
COVID-19–related neurologic involvement. B, Most abnormal laboratory results
in 1695 patients (age <21 years) with COVID-19 by severity of neurologic
involvement. Denominators varied and are provided in eTable 6 in
Supplement 1. FEU indicates fibrinogen equivalent units.
SI conversion factors: To convert C-reactive protein to mg/L, multiply by 10;
D-dimer to nmol/L, multiply by 5.476; hemoglobin to d/L, multiply by 10;
platelet count to ×109/L, multiply by 1.
a Neutrophilia was defined as a maximum absolute neutrophil count higher than
7700/μL.
b Lymphocytopenia was defined as an absolute lymphocyte count of less than
1500/μL in patients 8 months or older and of less than 4500/μL in patients
younger than 8 months.
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COVID-19 may have exacerbated an underlying pathophysi-
ologic state (eg, hypercoagulability, hyperinflammation, in-
creased risk of bleeding, and endothelial dysfunction) predis-
posing to stroke while receiving ECMO.64,65 The 4 cases without
stroke risk factors were directly associated with COVID-19. In
the pediatric literature consisting of case reports and 2 inter-
national case series, ischemic stroke type has been reported
in 18 children with COVID-19 with stroke mechanisms similar
to those observed in our study.44,66-69 Acute ischemic stroke
in hospitalized adults with COVID-19 is not uncommon.8,33,70
We also describe global cerebral involvement in 15 pa-
tients (8 with MIS-C) with severe encephalopathy, 8 patients
with acute CNS infection (encephalitis, aseptic meningitis) or
postinfectious, central demyelination (ADEM), and 4 pa-
tients with acute fulminant cerebral edema. We identified
5 previously healthy patients who presented with severe en-
cephalopathy, focal neurologic deficits, and visual hallucina-
tions (4 of 5 cases) and had diffuse abnormal T2 hyperinten-
sities and reduced diffusivity involving the white matter
and genu or splenium of the corpus callosum on MRI. These
imaging features have been ascribed to COVID-19 in adults50,71
and in children with MIS-C.44,51,52 Cytotoxic lesions in the
corpus callosum are thought to be associated with increased
numbers of glutamate and cytokine receptors in the corpus
callosum, particularly the splenium.44,72,73 Similar to the range
of outcomes in 1 small adult case series,50 3 patients had un-
favorable outcomes (1 died and 2 were discharged with
new deficits including cognitive impairment and painful
neuropathy requiring gabapentin). Of those with acute CNS
infections/ADEM, 7 patients in our study could be confirmed
as having probable acute CNS infection using published case
definitions.48,49 Case reports and small case series also sup-
port a link between meningoencephalitis and COVID-19 in
adults74-76 and children.44,77-79
There were 4 cases of previously healthy children who de-
veloped acute fulminant cerebral edema directly associated with
COVID-19 or MIS-C, and 3 died. Acute fulminant cerebral edema
has been previously reported in a child with COVID-1980 and is
a recognized phenotype with high mortality in adults81,82 and
children44,83 associated with other viral causes.
Our study has several strengths. There was expert adju-
dication of cases with fatal and life-threatening neurological
involvement and new neurologic deficits by pediatric neurol-
ogy, pediatric critical care, and pediatric neuroradiology ex-
perts. The central study team also had personal communica-
tion with site clinicians contributing cases with fatal and
life-threatening neurologic involvement or new neurologic
deficits to confirm diagnoses and clinical course. Neuroimag-
ing was associated with clinical information to document
supportive imaging findings and confirm diagnoses. We also
captured patients across most US states from a large number
of pediatric centers.
Limitations
The study has certain limitations. First, cases of COVID-19–
related neurologic involvement were identified only at report-
Table 2. Life-threatening COVID-19–Related Neurologic Conditions and Deaths in 43 Patients (Age <21 Years) Hospitalized for COVID-19
Variable












No. 43 15 12 8 4 4
Age, median (IQR), ya
12 (7-15)
1 Infant 1 Preschooler 1 Infant 1 Infant 2 School aged
1 Toddler 5 School-aged 1 Toddler 1 Preschooler 2 Adolescents
2 Preschoolers 5 Adolescents 2 Preschoolers 2 School-aged NA
5 School-aged 1 Young adult 1 School-aged NA NA
6 Adolescents NA 3 Adolescents NA NA
Male 27 (63) 11 (73) 6 (50) 4 (50) 2 (50) 4 (100)
RT-PCR or antibody results
Positive RT-PCR
result only
19 (44) 7 (47) 7 (58) 2 (25) 3 (75) 0
Positive antibody
result only
11 (26) 3 (20) 3 (25) 3 (38) 0 2 (50)
Positive RT-PCR and
antibody results
13 (30) 5 (33) 2 (17) 3 (38) 1 (25) 2 (50)
MIS-C diagnosis 20 (47) 8 (53) 3 (25) 6 (75) 2 (50) 1 (25)
No major underlying
conditions
34 (79) 11 (73) 8 (67) 8 (100) 4 (100) 3 (75)
Underlying neurologic
disorder
3 (7) 1 (7) 2 (17) 0 0 0
Death 11 (26) 4 (27) 4 (33) 0 3 (75) 0
Discharged alive,
new CNS deficit
17 (40) 2 (13) 7 (58) 5 (63) 0 3 (75)
Abbreviations: ADEM, acute disseminated encephalomyelitis; CNS, central
nervous system; COVID-19, coronavirus disease 2019; IQR, interquartile range;
MIS-C, multisystem inflammatory syndrome in children; NA, not applicable;
RT-PCR, reverse transcriptase–polymerase chain reaction.
a Age categories reported for privacy reasons for subcategories of
complications: infant (age <1 year), toddler (age 1-2 years), preschool (age 3-5
years), school-aged (age 6-12 years), adolescent (age 13-17 years), and young
adult (age 18-21 years).
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ing hospitals and may not accurately reflect the true range and
severity of COVID-19 neurologic involvement. Second, in pa-
tients with underlying neurologic diseases, neurologic pre-
sentations may be owing to COVID-19 neurologic effects or
exacerbation of underlying neurologic conditions. Third, not
all patients underwent neuroimaging (possibly owing to in-
fection control concerns or critical illness-related instability)
and image acquisition was not standardized, which could re-
sult in misclassification or an underestimation of neurologic
involvement. Fourth, although standardized case report forms
were used, we may not have captured certain variables com-
pletely, such as the indications for procedures (eg, lumbar punc-
ture and imaging). Fifth, some neurologic symptoms (eg, an-
osmia or ageusia) may be underreported in very young patients.
Sixth, nonstandardized diagnostic workups performed un-
der routine clinical conditions may have missed non–COVID-
19–related causes of life-threatening neurological conditions
attributed to COVID-19. Seventh, standardized and validated
assessments of neurologic outcomes at or after hospital dis-
charge were not performed, likely underestimating the na-
ture and extent of neurologic sequelae. Eighth, this is not a pro-
spective cohort study but a case series, and caution is warranted
in interpreting these data to identify risk factors for neuro-
logic involvement.
Conclusions
In this study, neurologic involvement was common in chil-
dren and adolescents with COVID-19–related hospitalization
Figure 2. Representative Central Nervous System Images From Patients With Life-threatening COVID-19–Related Neurologic Involvement
Meningoencephalitis (ADEM-like)A
Acute arterial ischemic strokeB Acute hemorrhagic strokeC
Acute fulminant cerebral edemaD Guillain-Barré syndromeE
Axial T2 FLAIR MR angiogram Sagittal T1 fat satwith contrast
Axial T1 with contrast
Axial diffusion MR angiogram Axial CT
Sagittal T2Axial SWIAxial T1 with contrastAxial T2 FLAIR Sagittal T1 with contrast
Axial CT
A, Young boy with headache, fatigue, and weakness. Enhancing cerebral lesions
with basal ganglia punctate blood products, and abnormal spinal cord signal
with focal nodular enhancement. B, Male adolescent with right-sided
hemiparesis, confusion, and conjunctivitis. Left middle cerebral artery infarct
with middle cerebral artery bifurcation intraluminal thrombus (arrow).
C, Adolescent with cerebral palsy in acute hypoxemic respiratory/kidney failure.
During recovery sudden respiratory decompensation and shock requiring
venovenous extracorporeal membrane oxygenation for 3 to 4 weeks. Computed
tomography (CT) for mental status change and anisocoria shows intraventricular,
subdural, and frontal intraparenchymal hemorrhage. D, Acute fulminant cerebral
edema. Young girl with altered awareness, seizure, nausea, vomiting, acute
respiratory failure, and shock requiring vasopressors. Severe cerebral edema
with reduced diffusivity and magnetic resonance (MR) angiography with little
flow above the level of the supraclinoid internal carotid arteries consistent with
brain death. E, Adolescent presents with lethargy, paresthesia, and extremity
weakness. There are enhancing cauda equina nerve roots. COVID-19 indicates
coronavirus disease 2019; fat sat, fat saturation; FLAIR, fluid-attenuated
inversion recovery; SWI, susceptibility weighted imaging.
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and is mostly transient. A spectrum of life-threatening neu-
rologic involvement infrequently occurred and was associ-
ated with more extreme inflammation and severe sequelae.
Future immunologic studies of cell-mediated and cytokine
immune responses in young individuals may provide insight
into the pathogenesis of neurologic disease in COVID-19 and
MIS-C.84 Patients with less severe neurologic involvement
could have future sequelae. Long-term follow-up of pediatric
patients with COVID-19–related neurologic involvement is
needed to evaluate effects on cognition and development.
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